The FDA has approved an expanded indication for Aptiom to treat pediatric partial-onset seizures.
Briviact was initially approved as adjunct treatment for partial-onset seizures.
Rectal diazepam is currently the only FDA-approved treatment for pediatric status epilepticus.
Over 1% of the US population reported active or current epilepsy in 2015.
While several studies have demonstrated efficacy in refractory epilepsy, it is still not clear how cannabidiol may have an impact on current epilepsy treatments.
Brexanolone may help wean patients with super-refractory status epilepticus off of third-line agents.
For people with seizures, levetiracetam is more effective than carbamazepine and lamotrigine.
In children with epilepsy, genetic investigation that emphasizes sequencing tests should be part of the initial evaluation.
Previous research has found a higher prevalence of depression before and after an epilepsy diagnosis.
The FDA has expanded the age range for the VNS Therapy system.
Potiga tablets have been discontinued due to the limited use of the medicine.
Woman with SLE complains of headache, confusion, and mild somnolence to the emergency department.
The FDA-sponsored study sought to evaluate the bioequivalence of 2 generic forms of the popular epilepsy treatment lamotrigine.
Epileptic phenomena are an important component of the dysfunction of the neuronal networks affected by Alzheimer's disease.
Anup Patel, MD, of Nationwide Children's Hospital and The Ohio State University School of Medicine, discusses findings from a dose-ranging study of cannabidiol for the treatment of drop seizures in Lennox-Gastaut syndrome. Scroll to below the video for a full text transcript of Dr Patel's interview.
Results from 2 phase 3 clinical trials demonstrated efficacy of adjunctive cannabidiol for the treatment of drop seizures in Lennox-Gastaut syndrome.
Cynthia Harden, MD, lead author of the new SUDEP guidelines, discusses the development process and what she hopes clinicians will take away from the guidance. Scroll to below the video for a full text transcript of Dr Harden's interview.
A newly published guideline shines light on sudden unexpected death in epilepsy and how clinicians can help prevent it.
Sepsis is associated with pathways that lead to permanent neurological sequelae.
In patients with lorazepam-resistant status epilepticus, treatment with lacosamide had comparable efficacy and safety as sodium valproate.
The International League Against Epilepsy has revised its epilepsy classification system in an effort to inform epilepsy research and aid drug development.
Sunovion has filed a supplemental NDA with the FDA to expand the indication for Aptiom to pediatric patients with partial onset seizures.
Elderly patients with neurologic comorbidities such as stroke or dementia had an increased risk for epilepsy or seizures.
Patients taking enzyme-inducing antiepileptic drugs and hormonal contraceptives face a greater risk of unintended pregnancy.
Participants reported improved adherence to a modified Atkins diet compared with the popular but restrictive ketogenic diet.
This study identified a feature of the epileptic brain that evolves slowly and differs fundamentally in well-controlled and poorly controlled epilepsy.
A diagnosis of maternal epilepsy alone was not associated with an increase in congenital malformations in offspring.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Functional MRI may provide a less-invasive option for evaluating memory function in patients undergoing epilepsy surgery.
Brain oxygenation may be compromised during periodic discharges, ultimately warranting treatment.
Neurology Advisor Articles
- Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence
- Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease
- MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics
- Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability
- The Handoff: Your Week in Neurology News - 9/21/17
- Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease
- Cognitive Decline Related to Site Specific Mid-Life Adiposity
- Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline
- Higher Doses of Pregabalin for Neuropathic Pain: Is it Safe?
- Buccal, Nasal Midazolam Most Cost-Effective for Pediatric Status Epilepticus
- Zika Virus Associated With High Risk for Neurologic Complications in Adults
- Evolocumab Has No Effect on Cognition in Patients Attaining Very Low Levels of LDL Cholesterol
- Acute Oxygen Therapy for Cluster Headahce Not Prohibitively Expensive
- β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD
- Little Evidence to Support Doctor, Patient Electronic Communication Guidelines